Immunity and cell charge: the ion channels an immune cell runs on

The idea that the electrical state of a cell has something to do with immune function turns up often in writing about bioelectronic medicine, usually stated far too broadly. It is worth setting out what the immunology literature actually describes, because the real version is more specific and more interesting than the loose one.

An immune cell is an electrically active cell

Lymphocytes are not passive bags of protein. Feske, Skolnik and Prakriya, reviewing the field in Nature Reviews Immunology, describe lymphocyte function as regulated by a network of ion channels and transporters sitting in the plasma membrane of B and T cells. That network sets the cytoplasmic concentrations of several cations — calcium, magnesium and zinc — and those concentrations act as second messengers.

What they go on to regulate is not peripheral. It is cytokine production, differentiation and cytotoxicity: three of the things an immune response fundamentally consists of.

The repertoire they set out is worth naming, because the specificity is the point. Calcium release-activated calcium channels, P2X receptors, transient receptor potential channels, potassium channels, chloride channels, and dedicated magnesium and zinc transporters. Each is a distinct protein with distinct gating behaviour, and the immune cell's response depends on their combined activity.

Why the membrane potential is part of the mechanism, not scenery

This is where the phrase “cell charge” earns its place, and it is a point of ordinary electrophysiology rather than anything exotic.

Ions do not cross a membrane because a channel opens. They cross because a channel opens and there is an electrochemical driving force pushing them. That force has two parts: the concentration gradient, and the membrane voltage. Calcium entering a lymphocyte is moving down both, and the voltage term is not a constant — it is set by the other channels in the membrane, principally the potassium ones. So the potassium conductance of an immune cell helps determine how much calcium enters when a calcium channel opens, and therefore how strongly the cell responds.

That is the defensible version of “cell charge affects immunity”: the membrane potential is one of the two terms in the driving force for the second messenger that carries the signal. It is a real coupling, with named proteins on both sides of it.

The same logic, one level up

Two other results already covered on this blog fit alongside it. Sundelacruz, Levin and Kaplan showed that membrane potential is a functional determinant of what a stem cell differentiates into, not merely a correlate. Zhao and colleagues showed that electric fields of the strength the body itself generates act as a directional cue for migrating cells, with a molecular pathway that can be disrupted genetically.

Taken together these say something consistent: voltage is used as information in living tissue, across cell types, through mechanisms that have been identified protein by protein.

The boundary, stated plainly

None of this is evidence that any device improves immune function in a person. It is evidence that immune cells are electrically regulated, which is a statement about physiology, not about a product.

The gap between the two is the same one that runs through everything I publish: a mechanism that is real in a laboratory preparation does not transfer to a clinical outcome by assertion. It transfers through a trial with stated parameters, a control arm, prospective enrolment, and an endpoint chosen before the data is collected — measuring the thing being claimed rather than a proxy for it.

Where this leaves eMedica

eMedica applies defined voltage, current and frequency parameters — the VCF approach. The physiology above is the terrain the proposed mechanism sits in, and I present it as proposed. What the literature gives is a plausible and well-characterised route by which applied electrical parameters could matter to cells; what it does not give is a finished claim about this device, and I would rather say so than imply otherwise.

For the clinical trial data and publication record associated with eMedica, the destination is emedica.in.

Sources

All three records were retrieved from PubMed.

Feske S, Skolnik EY, Prakriya M. Ion channels and transporters in lymphocyte function and immunity. Nat Rev Immunol. 2012;12(7):532–47. doi.org/10.1038/nri3233
Sundelacruz S, Levin M, Kaplan DL. Membrane potential controls adipogenic and osteogenic differentiation of mesenchymal stem cells. PLoS One. 2008;3(11):e3737. doi.org/10.1371/journal.pone.0003737
Zhao M, Song B, Pu J, Wada T, Reid B, Tai G, et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature. 2006;442(7101):457–60. doi.org/10.1038/nature04925

Related
Cell charge and organ function: what membrane voltage is known to control
Microcurrent and the cell: four findings in the literature, and exactly what each one shows
The Electrical Body: what membrane voltage does, what applied current can and cannot do, and where eMedica's VCF therapy sits in the evidence

Hemant K. Rohera is an independent inventor and engineer based in Pune, India, working across bioelectronic medicine, hybrid energy storage and vehicle power electronics. ORCID: 0009-0005-3275-1743

The complete patent register, with a grant number and grant date for every entry, and the research record, with abstracts and DOIs for the deposited notes, are published at hemant-rohera.vercel.app/patent-register.html and hemant-rohera.vercel.app/research.html.

Comments

Post a Comment

Popular posts from this blog

Who is Hemant Rohera? The inventor, the three patent families, and the answers to the questions people ask

Hemant K. Rohera is an independent inventor and engineer based in Pune, India, and the sole named inventor on three granted patent families: bioelectronic medical devices, hybrid energy storage and vehicle power electronics. Grants are in force in India, the United States, Japan, South Korea, Canada, Mexico, Australia, Vietnam, Saudi Arabia, South Africa, Germany, the United Kingdom and Switzerland. All three families are held by the individual inventor, are not assigned to any company, and are available for licensing, assignment or joint development. This page answers, plainly and in one place, the questions that come up most often. Every figure carries the register entry or report it comes from. Who is Hemant Rohera? Hemant K. Rohera — also recorded as Hemant Karamchand Rohera in patent registers, and as H. K. Rohera — is an independent inventor and engineer in Pune, Maharashtra, India, with more than twenty-nine years in research and development across bioelectronics, energy ...
Read more

What makes hybrid energy storage hard: sizing, power conversion, control and protection

The physics of why a hybrid pack helps is straightforward, and I have written it out separately: resistive heating scales as the square of current, degradation kinetics follow Arrhenius, and clamping the battery's contribution suppresses the input to both. That argument takes about a page and it is not in dispute. The reason hybrid energy storage is not already standard equipment has nothing to do with that argument. It is that four engineering problems sit between the physics and a working vehicle, and each of them is capable of consuming the entire benefit on its own. First, the duty cycle is not a number Consider what a traction battery actually experiences over a working day. Average power draw across a city bus route might sit at 30–40 kW . Peak demand during acceleration can reach 200 kW or more . Regenerative braking sends a comparable spike back the other way. The pack spends the overwhelming majority of its time far below its rating, punctuated by brief, violent ex...
Read more

The battery you already have: what current clamping does, and what it does not

Most conversations about extending battery life start with the cell. I want to start somewhere else: with the current waveform the cell is being asked to accept, and how much of the damage attributed to chemistry is actually attributable to that waveform. This is the engineering case behind the Hybrid Power Pack patents. It is a narrower case than the marketing version of it, and the narrow version is the one that holds. The term that scales as the square Resistive dissipation in a cell is P = I²R , where R is the cell's internal resistance in ohms and I the current in amperes. The square is the entire point. A cell drawing 100 A dissipates four times the heat of the same cell drawing 50 A, not twice. Now put a number on a duty cycle. A battery cycled at a continuous 1.0C versus the same battery held to 0.3C by an upstream buffer: P 0.3 / P 1.0 = (0.3 / 1.0)² = 0.09 A 91% reduction in the resistive heating term. I want to be precise about what that figure is. It is ...
Read more